Partners – Pneumo Update Europe 2025

More Information

Boehringer Ingelheim has over 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.

Check here for more information about www.boehringer-ingelheim.com

More Information

Chiesi is an international group based in Parma, research-oriented, with over 85 years of experience, present in 31 countries. The Chiesi Group researches, develops and markets innovative drugs in three specific areas: AIR (products and services in the respiratory field, from infants to adults), RARE (innovative solutions and personalized services to improve the quality of life of patients with rare and ultra-rare diseases) and CARE (products and services to support specialist care, personal care and well-being).

More Information

Bosch Healthcare Solutions GmbH is a wholly owned subsidiary of Robert Bosch GmbH. The subsidiary was established in 2015 with the aim of developing products and services that improve people’s health and quality of life. Nearly 300 associates (state 2024) are employed at the company’s headquarters in Waiblingen, Germany. The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.

Additional information is available online at www.bosch-healthcare.com, www.vivatmo.com, www.vivatmo-hcp.com, www.bosch-vivalytic.com.

More Information

NIOX – The global leader in FeNO testing

NIOX is dedicated to improving the diagnosis and management of respiratory diseases such as asthma. NIOX VERO®, the gold standard FeNO testing device, is accurate, reliable and easy-to-use by physicians and patients from the age of 4.

Our unique NIOX® technology is used by healthcare professionals worldwide to accurately assess Type 2 airway inflammation. FeNO testing is non-invasive and is performed in less than 2 minutes at the point-of-care. FeNO results support healthcare professionals to achieve more accurate diagnoses and better patient outcomes.